Boston biotech Jnana Therapeutics has raised $107 million in a Series C financing led by Bain Capital Life Sciences. The proceeds from the funding will be used to progress the company’s lead program in phenylketonuria (PKU), a rare genetic metabolic disease, through a clinical proof-of-concept (POC) study, and to advance additional wholly owned, potential first-in-class […]

Biogen has appointed Christopher Viehbacher as President and Chief Executive Officer and a member of the Board of Directors, effective November 14. Viehbacher succeeds Michel Vounatsos, who has led the company since 2017. Viehbacher has extensive international experience in both large pharmaceutical companies and entrepreneurial biotech companies. After 20 years with GlaxoSmithKline, he served as […]

Moderna and Merck have announced plans to jointly develop and commercialize a personalized cancer vaccine pursuant to the terms of its existing Collaboration and License Agreement. The vaccine, based on mRNA technology, is currently being evaluated for patients with high-risk melanoma in a Phase 2 clinical trial being conducted by Moderna. “We have been collaborating […]

Waltham-based giant Thermo Fisher Scientific is poised to acquire UK-based specialty diagnostics company The Binding Site Group for $2.6 billion, continuing a string of acquisitions spanning several years. Upon completion of the transaction, expected in the first half of 2023, The Binding Site will become part of Thermo Fisher’s Specialty Diagnostics segment. The Binding Site […]

Landmark Bio has announced the opening of its 44,000 square-foot, fully integrated development and manufacturing facility in Watertown. “This new state-of-the-art facility will bring together leading innovators from universities, research institutes, hospitals, and industries in the Greater Boston life science community,” said Alan M. Garber, M.D., Ph.D., chairman of Landmark Bio’s board of directors. “Landmark […]

Johnson & Johnson and Danvers-based Abiomed have entered into a definitive agreement under which J&J will acquire all outstanding shares of Abiomed, for an upfront payment of approximately $16.6 billion. Abiomed shareholders will also receive up to $35 per share in cash if certain commercial and clinical milestones are achieved. The transaction was unanimously approved […]